Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clopidogrel napadisilate
- Development stage
- Phase 4
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Clopidogrel napadisilate is a pharmaceutical compound that combines clopidogrel, a well-established antiplatelet agent, with napadisilate as a salt form. It is developed for the management of cardiovascular diseases, leveraging the antiplatelet action of clopidogrel. The mechanism of action involves irreversible inhibition of the platelet P2Y12 adenosine diphosphate (ADP) receptor, thereby preventing ADP-mediated platelet activation and aggregation, and reducing the risk of atherothrombotic events such as myocardial infarction and stroke[1][3][5].
- Other names
- clopidogrel napadisilate
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on clopidogrel napadisilate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clopidogrel napadisilate.